Analysis identifies key factors impacting adverse events of bortezomib in multiple myeloma, indicating the need for more evidence.
Background: Multiple myeloma (MM) is a plasma cell malignant tumor known for its high incidence rate. Bortezomib was the first proteasome inhibitor approved for MM. Many factors can result in bortezomib's adverse events, influencing its continuous treatment. It remains a controversial topic requiring more evidence to support its appropriate use.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: